To determine whether irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidines. 
INTRODUCTION
The benefits of chemotherapy as palliative treatment for advanced colorectal cancer (CRC) have been recognized for more than two decades. 1 Although fluorouracil (FU) plus leucovorin (LV) remains a key component of most regimens, the availability of oxaliplatin (Eloxatin; Sanofi-aventis, Bridgewater, NJ) and irinotecan (CPT-11; Camptosar; Pfizer Oncology, New York, NY/Campto; Astra Medical, Cambridge, United Kingdom) has increased the number of therapeutic options, transforming the treatment of advanced CRC.
Single-agent irinotecan is active as salvage therapy for metastatic CRC after disease progression on first-line fluoropyrimidines. 2, 3 Irinotecan significantly improved survival compared with either best supportive care 2 or a continuous infusion of FU, 3 leading to approval in 1996 in the United States as a second-line treatment for metastatic CRC.
Single-agent oxaliplatin is only moderately active for advanced CRC. 4, 5 However, the combination of oxaliplatin plus bolus/infusional FU and LV (FOLFOX) is superior to a regimen consisting of LV and FU (LV5FU2) alone after failure of irinotecan, bolus FU, and LV (IFL). 5 In a phase III study of 821 patients with disease progression with IFL, FOLFOX achieved an objective response rate (ORR) of 9.9% compared with 0% for LV5FU2 alone (P Ͻ .0001). Time to disease progression and relief of tumor-related symptoms were also improved with FOLFOX. 5 On the basis of these results, FOLFOX was approved for use in patients with advanced CRC after treatment failure of IFL.
There are strong clinical and preclinical rationales for combining irinotecan with oxaliplatin in metastatic CRC. First, preclinical studies have demonstrated a synergistic interaction between the two drugs. [6] [7] [8] [9] Second, the dose-limiting toxicities of the two drugs are largely nonoverlapping (diarrhea and myelosuppression for irinotecan and peripheral sensory neuropathy for oxaliplatin). In phase I/II studies of patients with advanced CRC previously treated with fluoropyrimidine-based chemotherapy, the combination of irinotecan and oxaliplatin (IROX) was active, achieving ORRs of 15% to 64% and median overall survival (OS) durations of 10.5 to 17 months.
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The present study was undertaken to compare IROX against the standard regimen of irinotecan alone in patients with metastatic CRC that had progressed or recurred during or after adjuvant or firstline fluoropyrimidines.
PATIENTS AND METHODS

Study Design and Treatment
This was a randomized, open-label, phase III study conducted at 118 centers in seven countries (Brazil, Canada, Czech Republic, Hungary, Poland, United Kingdom, and the United States). Eligible patients were assigned to IROX (oxaliplatin 85 mg/m 2 administered as a 120-minute intravenous [IV] infusion followed by irinotecan 200 mg/m 2 administered as a 30-or 90-minute IV infusion) every 3 weeks or to irinotecan alone (350 mg/m 2 administered as a 90-minute IV infusion) every 3 weeks. In the irinotecan group, patients age Ն 65 years or those who had received prior abdominal/pelvic radiotherapy or had elevated bilirubin levels received a starting dose of 250 mg/m 2 , with dose escalations to 300 or 350 mg/m 2 in the absence of grade Ն 2 toxicities. Patients were randomly assigned centrally via an interactive voice response system and stratified according to baseline Karnofsky performance status (KPS), number of organs with metastases, pretreatment lactate dehydrogenase, and prior treatment with FU or capecitabine. Treatment was administered until progressive disease.
Tumors were evaluated according to the Response Evaluation Criteria in Solid Tumors by computed tomography or magnetic resonance imaging. 17 Measurements were made at baseline (within 28 days before the first dose of study drug), every 6 weeks during treatment, 30 days after the last dose, and every 8 weeks after the 30-day poststudy visit until documentation of progression or until 13 months after the first dose of study medication (whichever came first). Any response had to be confirmed within 4 to 6 weeks. Best overall response was recorded at the end of the study. Clinical benefit was assessed at baseline (within 7 days before randomization and the first dose of study drug), every 3 weeks (before receiving chemotherapy), and then every 4 weeks for up to 3 months after the last dose of study medication. The assessment included administration of a tumor-related symptom (TRS) questionnaire (to selfassess pain intensity and KPS), evaluation of analgesic use by daily diaries, and investigator assessment of weight and KPS. The KPS value used in the clinical benefit analysis was the lowest of the assessments by the physician and patient. Patients were followed for survival until death. Treatment-related toxicities were assessed throughout treatment until 30 days after the final administration of study medication. Toxicities were graded according to National Cancer Institute Common Toxicity Criteria version 2.0. An oxaliplatin-specific scale was used to grade neurologic toxicity (grade 1, paresthesias/dysesthesias that may have been cold induced and do not interfere with function; grade 2, paresthesias/dysesthesias that may have been cold induced, interfering with function but not with activities of daily living; grade 3, paresthesias/dysesthesias that may have been cold induced, with pain or functional impairment and that also interfere with activities of daily living; grade 4, paresthesias/dysesthesias that are disabling or life-threatening; acute, during or just after the oxaliplatin infusion).
The institutional review board or ethics committee at each site approved the protocol, which complied with the Declaration of Helsinki and all applicable amendments. All patients gave written informed consent. An independent Data and Safety Monitoring Board convened approximately every 6 months to review enrollment procedures, safety, and other issues related to the conduct of the trial.
Patients
Eligibility criteria included age Ն 18 years; measurable or nonmeasurable, histologically or cytologically proven, inoperable, metastatic or recurrent adenocarcinoma of the colon or rectum; disease progression or recurrence during or after first-line treatment with FU with or without LV or capecitabine, or relapse during or within 6 months of adjuvant FU/LV; and prior chemotherapy for metastatic or recurrent disease (maximum of one regimen, without prior oxaliplatin or irinotecan) completed Ն 3 weeks before random assignment, with all acute or delayed toxicities resolved. Patients had to be medically stable with a KPS Ն 70%, adequate organ function, and no existing peripheral neuropathy.
Statistical Analysis
The primary end point of OS was analyzed using a two-sided unstratified log-rank test; median values and 95% CIs were calculated. The timing of the primary survival analysis was prespecified as the date when a total of 447 patients had died. A secondary survival analysis was conducted using all available data. Overall, 298 patients per arm were required to provide 85% power to detect an increase in median OS from 9 months in the irinotecan arm to 12 months in the IROX arm, using a two-sided log-rank test at the P Ͻ .05 level. Secondary objectives included evaluation of ORR, onset and duration of response, time to progression (TTP), clinical benefit, and treatment-related toxicities. The ORR was analyzed using a two-sided Fisher's exact test, and TTP was analyzed using a two-sided unstratified log-rank test, both at the P Ͻ .05 level. Survival curves were plotted using Kaplan-Meier methodology.
The primary clinical benefit parameter, time to tumor-related symptomatic worsening (TTSW), was defined as the time from random assignment until the patients worsened with respect to KPS, pain, or analgesic consumption. Worsening was defined as the date of first observation of a change (Ͼ 2 cm increase in pain [on the visual analog scale], Ն 50% increase in analgesic consumption [reaching Ն 10 mg/d morphine equivalents], and/or Ն 20-point decrease in KPS from baseline) that subsequently persisted for Ն 4 weeks. TTSW was analyzed using a two-sided unstratified log-rank test. The proportions of symptomatic patients (baseline: KPS Յ 80%, pain score Ͼ 2 cm, consumption of Ն 10 mg/d morphine equivalents for disease-related pain over the 7 days before study entry, and/or weight reduced by Ͼ 10% from usual level) with improvement in TRS (change from baseline: Ͼ 2-cm decrease in pain, Ն 50% decrease in analgesic consumption, Ն 20-point increase in KPS, and/or Ն 5% increase in weight) were compared between the two arms using a 2 test. Any improvement had to be sustained for Ն 4 weeks. Association of improvement in TRS and objective response was assessed using the Spearman correlation coefficient. Efficacy analyses were conducted on the intent-to-treat population.
RESULTS
Patient and Tumor Characteristics
From January 23, 2001, to April 30, 2004, a total of 628 patients were randomly assigned to receive IROX (n ϭ 318) or irinotecan (n ϭ 310). All patients who received study medication (313 in the IROX group and 301 in the irinotecan group) were included in the safety population. Five patients in the IROX arm were randomly assigned and not treated (three patients because of ineligibility, two patients because of refusal). Nine patients in the irinotecan arm were randomly assigned and not treated (two patients withdrew consent, three patients developed disease progression before treatment, two patients were ineligible, and two patients withdrew).
Patient characteristics and stratification factors were similar between the treatment groups (Table 1) . After a meeting of the Data and Safety Monitoring Board (August 2001), the primary statistical test was changed from a stratified (for KPS) log-rank test to an unstratified log-rank test as a result of protocol revisions, which required patients to have a KPS Ն 70%. Stratification data for KPS were not collected from that point forward.
Treatment Administered
The median number of cycles administered per patient was six (range, one to 22 cycles) in the IROX group and four (range, one to 28 cycles) in the irinotecan group. More IROX-than irinotecan-treated patients experienced one or more treatment delay (52% v 31%, respectively). Eight patients (3%) in the IROX group and four patients (1%) in the irinotecan group completed dosing (on study for Ն 1 year having received Ն 15 cycles). Among the intent-to-treat patients who discontinued (IROX, n ϭ 317; irinotecan, n ϭ 310), reasons included disease progression (IROX, 54%; irinotecan, 66%), toxicity (IROX, 13%; irinotecan, 13%), investigator or patient refusal (IROX, 16%; irinotecan, 10%), death (IROX, 1%; irinotecan, Ͻ 1%), and other (IROX, 13%; irinotecan, 10%). Toxicity was the most common reason for delay (33% v 13% of patients, respectively). Similarly, more patients in the IROX group had one or more cycle of irinotecan administered at a reduced dose (43% v 23%, respectively). Twenty-six percent of IROX-treated patients had one or more cycle of oxaliplatin administered at a reduced dose. The median relative dose-intensity for irinotecan was 92% and 86% in the IROX and irinotecan groups, respectively. In the IROX group, the median relative dose-intensity for oxaliplatin was 94%. Overall, 57% of IROX-treated patients and 64% of irinotecantreated patients received third-line treatment; 21% and 28%, respectively, received fourth-line therapy. More patients in the irinotecan group than in the IROX group went on to receive oxaliplatincontaining chemotherapy as third-line ( 
Response to Therapy
Median follow-up was 19.6 months (95% CI, 19.2 to 20.6 months). In the primary analysis (prespecified as the date when a total of 447 patients had died), median OS was 13.4 months (95% CI, 12.4 to 14.7 months) in the IROX group and 11.1 months (95% CI, 10.0 to 12.7 months) in the irinotecan group (hazard ratio ϭ 0.78; 95% CI, 0.65 to 0.94; P ϭ .0072; Fig 1) . In a secondary survival analysis that was conducted using all available data (no data cutoff), median OS was also superior in the IROX group (13.8 v 11.1 months; P ϭ .0069).
The ORR was significantly higher in the IROX group than in the irinotecan group (Table 2 ). The tumor control rate and time to onset of response also favored IROX (Table 2) . Median TTP was significantly longer in the IROX group (5.3 months; 95% CI, 4.7 to 5.7 months) than in the irinotecan group (2.8 months; 95% CI, 2.6 to 3.3 months; hazard ratio ϭ 0.60; 95% CI, 0.51 to 0.70; P Ͻ .0001; Fig 2) .
Significantly more patients in the IROX group experienced an overall improvement in TRS (composite score) compared with those in the irinotecan group (P ϭ .0072; Table 3 ). Pain and analgesic use were the most improved parameters. Median TTSW was 7.6 months (95% CI, 6.4 to 11.5 months) in the IROX group and 4.4 months (95% CI, 3.1 to 5.8 months) in the irinotecan group (P ϭ .0073). A positive correlation was observed between objective tumor response and symptom improvement in the subpopulation of 396 symptomatic patients (Spearman rank correlation coefficient 0.29; P Ͻ .0001). A similar positive correlation was observed between tumor control and symptom improvement (correlation coefficient 0.37).
Safety and Tolerability
Diarrhea and nausea were the most common toxicities in the treatment groups (diarrhea, 85% and 77% of patients in the IROX group; nausea, 78% and 66% of patients in the irinotecan group). Grade 3 to 4 toxicities that were more common in the IROX group than in the irinotecan group included granulocytopenia, diarrhea, and sensory disturbance (Table 4) . The nature and incidence of other individual grade 3 to 4 toxicities were comparable between treatment groups. Although the overall incidence of sensory neuropathy was 58% in the IROX group and 9% in the irinotecan group, the incidence of grade 3 neuropathy was 6% and 0.3%, respectively; no grade 4 neuropathy was observed. Grade 3 cumulative neuropathy (paresthesia) occurred in 1% of patients in the IROX group and in no patients in the irinotecan group.
The proportion of patients with any serious toxicity was similar in the two groups (IROX, 32%; irinotecan, 33%). The most common serious toxicities in the IROX group were diarrhea (9%), febrile neutropenia (6%), vomiting (5%), and neutropenic sepsis (5%). In the irinotecan group, the most common serious toxicities were diarrhea (9%), vomiting (7%), febrile neutropenia (7%), nausea (6%), and neutropenic sepsis (3%). Cause of death overall was attributed to adverse events in nine patients (3%) in the IROX group and five patients (2%) in the irinotecan group. In the IROX group, 13 patients (4.2%) died within 30 days of the last dose of study drug; eight patients (2.6%) died from adverse events and five patients (1.6%) died of progressive disease. On irinotecan alone, 17 patients (5.6%) died within 30 days of last dose; five patients (1.7%) died from adverse events, 11 patients (3.7%) died from disease progression, and one patient died of an unknown cause.
DISCUSSION
In this difficult-to-treat patient population with refractory or resistant metastatic CRC, second-line IROX demonstrated improved efficacy compared with irinotecan monotherapy for all end points (OS, ORR, onset of response, tumor control rate, TTP, TRS, and TTSW). Notably, IROX improved the median OS by 2.3 months compared with irinotecan, generally accepted as a clinically relevant prolongation of survival in this setting. This benefit was achieved despite the fact that a high proportion of patients who experienced disease progression while being treated with irinotecan alone received salvage treatment with oxaliplatin, either as monotherapy or in combination with FU/LV.
Toxicities with IROX were predictable and manageable, and oxaliplatin and irinotecan in combination did not seem to adversely affect safety compared with the toxicity profile of either agent alone. The majority of toxicities were gastrointestinal, and the incidence of serious toxicities and withdrawals because of toxicities was comparable between the two groups. Severe granulocytopenia was more common in the IROX group, but this did not translate into an increased incidence of febrile neutropenia, neutropenic sepsis, or toxicityrelated deaths. Although the incidence of severe diarrhea, a doselimiting toxicity of irinotecan, was slightly higher in IROX-treated patients, the increase of less than 5% was not considered to be clinically significant. All patients who experienced diarrhea received intense loperamide therapy. Clinically significant sensory neuropathy was uncommon in the IROX group, likely because of the dosing schedule and the total dose delivered, and only three patients in this group had cumulative grade 3 neuropathy.
Assessment of TRS, pain (analgesic consumption and pain intensity), KPS, and weight provides an indication of the clinical benefit associated with treatment. 18, 19 Patients treated with IROX experienced a greater improvement in TRS, in particular pain intensity and analgesic use, than patients treated with irinotecan alone, suggesting that treatment with IROX may confer a meaningful clinical benefit to such symptomatic patients. Although TTSW was prolonged with IROX, it is difficult to make any definitive inferences from these data because of heavy censoring, which accounted for approximately 65% of observations in each group. Interestingly, a positive correlation was observed between tumor burden and symptomatic improvement, indicating that patients who respond to treatment or achieve stable disease also have an improvement in TRS.
The OS of patients treated with single-agent irinotecan in the present study is similar to or slightly better than that reported previously for phase III studies in similar populations. 2, 3 In these studies, which compared second-line irinotecan with best supportive care 2 or continuous-infusion FU, 3 the reported median OS durations for irinotecan were 9.2 and 10.8 months, respectively.
The efficacy and tolerability of the IROX combination is similar to previous phase I/II results with this regimen, 10-16 which demonstrated ORRs of 15% to 64% and median OS durations of 10.5 to 17 months with second-line IROX after treatment failure with FU. The results of the present study are also in line with observations in the first-line setting, which show the OS benefit of patients receiving all three active agents (oxaliplatin, irinotecan, and FU/LV) over the course of their treatment. 20, 21 It is still uncertain regarding which patients require first-line combination chemotherapy, and in what sequence. Regarding the relevance of these results, many patientswith estimates as high as 20% to 25%-still receive first-line singleagent fluoropyrimidines, and many need tolerable and easily administered second-line regimens, such as IROX, as do patients who experience treatment failure with adjuvant therapy with FU/LV or capecitabine.
In practice, the choice of second-line therapy ultimately depends on the previous therapy received by the patient, in addition to the response and toxicity associated with that therapy. Since the present study was initiated, two regimens (FOLFOX and FOLFIRI [irinotecan plus LV5FU2]) have emerged as standard first-line treatments for metastatic CRC. In addition, targeted agents are increasingly being added to combination chemotherapy regimens in an attempt to further improve outcomes in both the first-and second-line treatment settings. For example, preliminary results from the phase III Eastern Cooperative Oncology Group 3200 study show that second-line FOLFOX plus bevacizumab can significantly improve median OS compared with FOLFOX alone (12.5 v 10.7 months, respectively; P ϭ .0024). 22 Even with these advances, IROX offers an additional useful and effective treatment option for appropriate patients with previously treated metastatic CRC. 
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